R-Biopharm Neugen Private Limited, a active private limited company, was established on 21 May 1997 in Hyderabad, Telangana, India. Engaging in medical equipment retail & distribution within the trade sector, it holds CIN: U74220TG1997PTC098579. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹8.00 M and a paid-up capital of ₹7.83 M.
Formerly known as Harmony Hi-Tech (Madras) Private Limited, Neugen Diagnostics India Private Limited. It upholds a compliant status. Employing 26 professional, Its leadership includes Shivani Bhadresh Desai (Director), Christian Moraeno Dreher (Director). Past directors included Subrahmanyam Chintalapati, Hariharan Ramalingam Balakrishnampathi, Padmakar Janardan Moghe. It holds ₹1.19 Cr open charges and no settled loans. Its latest AGM occurred on 27 June 2025, with the balance sheet filed on 31 December 2024. It is based at First Floor, Plot No.70/ Part 71, Road No 3, Ida, Phase I , Cherlapally, Hyderabad, Telangana, 500051.
U74220TG1997PTC098579
098579
21 May 1997
₹8.00 M
₹7.83 M
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into R-Biopharm Neugen Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shivani Bhadresh Desai | Director | 04 Mar 2021 | Current |
| Christian Moraeno Dreher | Director | 24 Oct 2013 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Whole-Time Director | 31 Jan 2010 | Past |
| Pramod Abcsdd | Additional Director | 15 Sep 2010 | Past |
| Pramod Abcsdd | Director | 24 Oct 2013 | Past |
| Pramod Abcsdd | Director | 24 Oct 2013 | Past |
| Pramod Abcsdd | Additional Director | 16 Apr 2014 | Past |
| Pramod Abcsdd | Additional Director | 29 Jun 2021 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
R-Biopharm Neugen Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.25% decrease. The company also saw a substantial fall in profitability, with a 536.47% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.38%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, R-Biopharm Neugen had a promoter holding of 100.00%. The company had 2 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹11,915,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 May 2020 | Others | ₹1.00 M | Open |
| 18 Oct 2012 | Corporate Bank | ₹1.09 Cr | Open |
Explore comprehensive loan charge details -
R-Biopharm Neugen has a workforce of 26 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of R-Biopharm Neugen, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R-Biopharm Neugen's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on R-Biopharm Neugen Private Limited last Annual general meeting of members was held on 27 Jun 2025 as per latest MCA records. was documented.
R-Biopharm Neugen Private Limited has filed its annual Financial statements for the year ended 31 Dec 2024 with Roc Hyderabad. was recorded as a recent event.
The activity Shivani Bhadresh Desai was appointed as a Director was appointed as a Director on 04 Mar 2021 & has been associated with this company since 4 years 10 months . was completed.
Progress on A charge with Others amounted to Rs. 1.00 M with Charge ID 100405168 was registered on 04 May 2020. was documented.
Progress on Christian Moraeno Dreher was appointed as a Director was appointed as a Director on 24 Oct 2013 & has been associated with this company since 12 years 2 months . was documented.
A charge with Corporate Bank amounted to Rs. 10.92 M with Charge ID 10385300 was registered on 18 Oct 2012. was recorded as a recent event.
The CIN of R-Biopharm Neugen Private Limited is U74220TG1997PTC098579.
R-Biopharm Neugen Private Limited is headquartered at First Floor, Plot No.70/ Part 71, Road No 3, Ida, Phase I , Cherlapally, Hyderabad, Telangana, 500051.
R-Biopharm Neugen Private Limited was incorporated on 21 May 1997.
The current directors of R-Biopharm Neugen Private Limited are
The primary industry of R-Biopharm Neugen Private Limited is Trade.
R-Biopharm Neugen Private Limited is unlisted.
The authorized capital of R-Biopharm Neugen Private Limited is ₹8.00 M, and the paid-up capital is ₹7.83 M.
The compliance status of R-Biopharm Neugen Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX